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Meningococcal meningitis remains a substantial cause of mortality
and morbidity worldwide. Until recently, countries in the African
meningitis belt were susceptible to devastating outbreaks, largely
attributed to serogroup A Neisseria meningitidis (MenA). Vaccina-
tion with glycoconjugates of MenA capsular polysaccharide led to
an almost complete elimination of MenA clinical cases. To under-
stand the molecular basis of vaccine-induced protection, we gen-
erated a panel of oligosaccharide fragments of different lengths
and tested them with polyclonal and monoclonal antibodies by
inhibition enzyme-linked immunosorbent assay, surface plasmon
resonance, and competitive human serum bactericidal assay,
which is a surrogate for protection. The epitope was shown to
optimize between three and six repeating units and to be
O-acetylated. The molecular interactions between a protective
monoclonal antibody and a MenA capsular polysaccharide frag-
ment were further elucidated at the atomic level by saturation
transfer difference NMR spectroscopy and X-ray crystallography.
The epitope consists of a trisaccharide anchored to the antibody
via the O- and N-acetyl moieties through either H-bonding or CH–π
interactions. In silico docking showed that 3-O-acetylation of the
upstream residue is essential for antibody binding, while O-acetate
could be equally accommodated at three and four positions of the
other two residues. These results shed light on the mechanism of
action of current MenA vaccines and provide a foundation for the
rational design of improved therapies.
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Capsular and other surface polysaccharides (PS) are majorvirulence components on bacterial cell surfaces and play
critical roles in immune system evasion, acting as the primary
interface for the host cells, and thus are considered attractive
vaccine targets (1, 2). Mapping glycan antigenic determinants,
recognized by bactericidal antibodies mediating protection from
microbial infections, is of paramount importance to reveal suit-
able antigenic structures for immune response elicitation (3).
However, the glycotope determinants and their bioactive con-
formations responsible for immunologic events are poorly un-
derstood, owing to the intrinsic flexibility and heterogeneity of
bacterial PS.
Recent advances in carbohydrate synthesis, providing access to
well-defined glycans, together with high-throughput glycoarrays
or microfluidic tools, such as surface plasmon resonance (SPR),
have fast tracked the screening of glycan-based antigens against
different pathogens, such as Clostridium difficile (4) and Strep-
tococcus pneumoniae (5). Structural identification of epitope
determinants and their conformations can be attained in solution
by NMR spectroscopy augmented by molecular dynamics (6), as
recently featured in the development of a vaccine candidate
against Burkholderia pseudomallei (7, 8). Paratope-epitope
molecular determinants of interactions can be further disen-
tangled at atomic resolution by X-ray crystallography. However,
crystallization of glycan-Fab complexes has proven to be far
more challenging than crystallization of protein antigen-Fab
complexes, putatively due to glycan’s greater flexibility and
lower affinity compared with proteins (9). Over the past decades,
several examples of glycan structural epitopes resolved at atomic
resolution by X-crystallography have been reported, including
Salmonella typhimurium lipopolysaccharide (10), Vibrio cholerae
O1 (11), Shigella flexneri serotype 2a O-antigen (12), Mycobac-
terium tuberculosis PS (13), and group B Streptococcus PS (14).
Understanding the structural basis of antigen-antibody binding
events offers the promise for a guided rational design of inno-
vative synthetic vaccines (15, 16), and glycomimetics (17, 18).
Invasive meningococcal disease is a daunting public health
concern, mainly because of its rapid clinical onset. Historically,
MenA has been considered a primary causative agent of sporadic
and epidemic outbreaks, especially in the so-called “meningitidis
belt” (19). An incidence of 10 to 1,000 cases per 100,000 pop-
ulation was reported (20), with MenA responsible for 70% to
96% of the cases before 2010 (21). Collective efforts in the
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PATH project with the development of MenAfriVac (22), along
with vaccination campaigns, resulted in a disease incidence re-
duction of >99% (23).
MenA capsular PS is composed of N-acetyl-D-mannosamine
moieties, α (1→6)-linked through phosphodiester linkages and
partly O-acetylated at C-3 or C-4 (24–26). Early studies proposed
that glycan chain length and O-acetylation pattern as key pa-
rameters for optimal immunogenicity of MenA vaccines. A
Phase I clinical trial of a MenA oligosaccharide (OS) with an
average chain length of 6 to 10 repeating units (RUs) conjugated
to the diphtheria toxoid CRM197 showed it to be both safe and
immunogenic (27). In contrast to many surface PSs, including
those from Shigella spp and other meningococcal serogroups (28),
O-acetylation has been hypothesized to play a critical role in
MenA PS immunogenicity (29). Antibodies from immunized
subjects were shown to preferentially recognize O-acetylated
moieties, while de-O-acetylated PS conjugate resulted in a
marked reduction of immunogenicity and, crucially, of the ability
to induce bactericidal antibodies in murine models (30). Recently,
in silico models have shown that MenA PS is presented either as
an extended conformation or as a compact hairpin bend, with the
conformational preference modulated by O-acetylation (31). Im-
portantly, O-acetyl groups are solvent-exposed, making them ac-
cessible for intermolecular interactions (32).
Starting from this evidence, we envisaged the study of the
interactions between MenA PS and bactericidal antibodies as a
powerful means to provide insight into key immunologic deter-
minants of this PS. We applied a combination of complementary
techniques to map the structural epitope of O-acetylated MenA
PS. A panel of MenA OSs of different lengths was generated by
depolymerization of MenA plain PS, and competitive enzyme-
linked immunosorbent assay (ELISA) and SPR were used to
assess inhibition and binding kinetics to a bactericidal mAb.
Saturation transfer difference (STD)-NMR, X-ray crystallogra-
phy, and molecular dynamics were exploited to unravel the
molecular basis of epitope-paratope recognition. Our findings
explain how O-acetyl moieties portray functionality to MenA
epitopes and may lead to a profound understanding about pro-
tective immunity against MenA.
Results
Generation and Screening of an MenA OS Library for Structural
Epitope Mapping. To describe the binding events of a protective
MenA mAb toward antigenic MenA OS, a bactericidal murine
mAb produced from a MenA conjugate was selected. The mAb
was initially obtained by classic hybridoma technology (MenA
1.1, hSBA titer: 0.04 μg/mL; rSBA titer: 0.005 μg/mL; SI Ap-
pendix, Table S1). For crystallography studies, after mRNA se-
quencing, codon-optimized cDNA was recombinantly expressed
in human Hek293 cells (mAb A1.3, hSBA titer: 0.03 μg/mL;
rSBA titer: 0.004 μg/mL; SI Appendix, Table S1). Subsequently, a
panel of MenA OS fragments was generated by mild hydrolysis
of the native PS (Fig. 1A). The reaction was quenched when an
average degree of polymerization (DP) of 5 was obtained, as
confirmed by 31P-NMR (Fig. 1B). Single DP fragments were
sized by anionic-exchange chromatography (33), allowing the
isolation of OSs ranging from DP1 to DP7 (Fig. 1C). The identity
and acetylation degree (SI Appendix, Fig. S1A and Table S2) of
the produced semisynthetic fragments were confirmed by
1H-NMR spectroscopy (34), which revealed an acetylation de-
gree of 70 to 75% at C-3 and 9 to 12% at C-4. The DP was
further corroborated by 31P-NMR and high-performance liquid
chromatography with pulsed amperometric detection profiling
(35) (SI Appendix, Fig. S1B).
Length and O-Acetylation Dependency of MenA Epitope. The binding
of anti-serogroup A murine sera toward the generated oligomers
was first assessed by inhibition ELISA, using native PS- coated
plates. Preincubation of the polyclonal serum with the OSs of
different lengths showed a length-dependent inhibition, with
serial dilution of the inhibiting fragments yielding a dose–
response curve (SI Appendix, Fig. S2 A and B and Table S3). Of
note, DP2 revealed a half maximum inhibitory concentration
(IC50) of 8.96 × 10
−2 mM, while the introduction of an additional
RU (DP3) led to a half-log reduction in the IC50 (2.01 × 10
−2
mM). A subsequent equivalent but progressive decrease in the
IC50 was observed from DP3 to DP6 (IC50 = 3.59 × 10
−3 mM),
whereby this fragment inhibited with IC50 comparable to frag-
ments longer than 20 RUs (Fig. 2A). The selected bactericidal
murine mAb showed a similar profile of inhibition as the poly-
clonal serum (Fig. 2A and SI Appendix, Fig. S2 A and B). Re-
markably, an increase of 1.5 log was observed between DP6
(IC50 = 4.17 × 10
−3 mM) and its de-O-acetylated congener
(IC50 = 1.91 × 10
−1 mM), revealing that the recognition is largely
abolished when the O-acetyl moieties are removed.
Next, the binding kinetics and affinity of different MenA
oligomers to the bactericidal mAb A1.3 were characterized by
SPR. Biotin neoglycoconjugates were prepared for immobiliza-
tion on the surface of a streptavidin-coated chip by reductive
amination of the OS, followed by acylation with a biotin-active
ester (SI Appendix, Scheme S1). Of note, the definition of the
DP-biotin conjugates considers only the number of unmodified
RUs, since the reductive amination procedure used for preparing
the neoglycoconjugates leads to the ring opening of the reducing
moiety (Fig. 2B). The neoglycoconjugates were immobilized at a
level ranging from 5 to 10 RU to avoid potential rebinding, and
thereafter the mAb was flown over the immobilized OS.
The protective antibody bound to and dissociated from the
glycoconjugates with fast on and off rates within nanomolar af-
finity, revealing a rapid attachment, which could play a role,
Fig. 1. Hydrolysis and sizing of MenA native PS into a well-defined length
OS library. (A) Native MenA PS underwent controlled mild acidic hydrolysis.
(B) Depolymerization was monitored by 31P-NMR. The DP was calculated as
[(PIntraglycosidic/PTerminal) + 1]. The spectrum of the native MenA PS (Top)
revealed only the phosphodiester moieties, while the phosphomonoester
regions were initially absent due to their lower abundancies. The spectrum
of the crude reaction mixture (Bottom) exhibited the appearance of the
phosphomonoester resonances, confirming the depolymerization of the PS
down to an avDP 5. (C) Preparative FPLC AEC (Q Sepharose) was used as a
size-fractioning step, with a linear gradient of NaCl, to isolate single DP OSs.
OSs with longer DPs (gray box) were pooled to originate a population with
avDP 20.







































especially in environments crowded with PS, such as pathogen
cell surfaces, favoring a swift complement-mediated killing of the
bacteria. The binding was specific, as demonstrated by the lack of
binding with a meningococcal serogroup C mAb (Fig. 2C).
Dissociation constants were determined using a 1:1 Langmuir
binding mode (Fig. 2C). The largest increase in affinity was ob-
served from DP2 to DP5 (Fig. 2D and SI Appendix, Table S4).
For the mAb-MenA DP5 complex, we determined a dissociation
constant, KD, of 3.9 × 10
−9 (± 2.0) M, with a dissociation rate
constant, koff, of 1.1 × 10
−3 s−1 (± 0.2) and an association con-
stant, kon, of 3.3 × 10
5 (± 1.0) M·s−1. The kon values were very
similar for DP2 and DP3 and exhibited a monotonical increase
from DP3 to DP6 (Fig. 2E), which could be explained by a faster
association as a result of greater preorganization of epitopes with
increased lengths, since the binding events usually occur with loss
of intrinsic conformational flexibility, and, consequently, entro-
pic penalties are likely to have higher contributions for shorter
and disordered epitopes (36). On the other hand, koff plateaus at
a length of 3 RUs (Fig. 2E), suggesting that a trimer accounts for
the majority of enthalpic contributions, while additional RUs in
longer oligomers are positioned outside of the binding pocket.
Overall, the resulting reduction in the KD value for longer
structures could be attributed to a concomitant reduction of
conformational entropy penalties, arising from epitope regions
conformationally constrained outside the binding pocket (37),
while their enthalpy term would remain constant on a length of 3
RUs, since this would suffice to fill the binding pocket. Re-
markably, the de-O-acetylation of DP5 (KD = 6.9 × 10
−5 M;
koff = 0.3 s
−1; kon = 4.8 × 10
3 M·s−1), resulted in a 4-log increase
in dissociation compared with the native DP5. This large abro-
gation in binding on removal of O-acetyl groups confirms the
central role of these moieties in the attachment in the ligand-
binding groove.
Remarkably, when the binding affinity was measured using the
recombinant Fab, the KD values were 2- to 5-fold lower,
depending on the DP tested, compared with those obtained with
the mAb (SI Appendix, Table S5 and Fig. S6). This clearly indi-
cates that data from the intact antibody were mostly the result of
a 1:1 binding modality.
Identification of Antigenic Determinants of Interaction by Solution
NMR. To map relevant positions of the MenA oligomers in-
volved in the binding events, considering that the binding affinity
optimized at the length of DP6, this OS and its de-O-acetyl
Fig. 2. Competitive ELISA and binding kinetics of a protective mAb to MenA-biotin conjugate OSs of different lengths by SPR. (A) Competitve ELISA (IC50) of
specific polyclonal serum (black) and monoclonal (gray) antibodies against native MenA PS, as a coating agent, evaluated with MenA OSs of different lengths.
Inhibition curves and IC50 of the different OSs for polyclonal serum and mAbs are reported in (SI Appendix, Fig. S2 A and B and Table S3). (B) Chemical
structure of OS-biotin fragments immobilized in streptavidin chips. (C) SPR showing a concentration-dependent binding of a protective mAb to MenA DP5-
biotin, with no binding observed using a anti-MenC antibody. Binding kinetics and rate constants for OSs of different lengths were inferred by fitting the
experimental data with a 1:1 Langmuir binding model. (D) Structure of the biotylinated MenA OS and the effect of length on affinity for a range of OSs. (E
and F) On-rate kinetics (M−1 s−1) (E) shows a gradual increase, while off-rate kinetics (s−1) (F) reveals a steep decrease in mAb dissociation when a third RU unit
is introduced. Bars represent mean of the data, and the error bars represent the SD of the mean. Values are reported in SI Appendix, Table S4, and raw
sensorgrams are provided in SI Appendix, Figs. S3–S5. A comparison with binding of the Fab is shown in SI Appendix, Fig. S6.



























































congener were selected for STD-NMR epitope mapping (38).
Considering that the nM KD affinity of the acetylated DP6 was
due primarily to a low dissociation rate, its spectrum was
recorded at a temperature of 303 K to increase the turnover due
to tight binding and to minimize avidity. Consistent with the
previous observations, the STD-NMR spectrum of DP6 (Fig. 3 A
and B) revealed that methyl protons of the O-acetyl groups
represent the moieties receiving the highest transfer of satura-
tion (100%), confirming that these determinants are major an-
choring points for mAb interactions.
The methyl protons of N-acetyl moieties receive a relative
70% saturation, indicating their direct engagement with the
antibody as well. Of note, the DP6 is O-acetylated at 74% at C-3
and 13% at C-4; thus, 3-O-, 4-O-, and 2-N-acetyls appear strongly
engaged in interactions on complex formation. Because of the
nanomolar affinity of the DP6, some proton signals of the ring
were poorly amplified. To better understand the role of acety-
lation, the STD-NMR of the de-O-Ac DP6 fragment was mea-
sured. STD-NMR (Fig. 3A) revealed that the proton H4 was
receiving a greater amount of saturation (100%), higher than
that of H3 (63%), indicating that on removal of the O-acetyl
groups, position 4 as well as position 3 could be exposed in
proximity of the binding pocket. Overall, consistent with the
ELISA and SPR data, these results indicate that the acetylation
pattern of MenA PS plays a pivotal role in the binding events
(Fig. 3C).
Structural Insights into the Molecular Mechanism of Recognition of a
Protective Epitope. To gain further insight into the molecular
basis of recognition, the MenA DP6 OS was also crystallized in
complex with the Fab fragment derived from the protective
recombinant mAb A1.3 Fab. Crystals of the complex Fab:DP6
diffracted at 2.67 Å resolution. The complex was refined to final
Rwork/Rfree values of 21%/26.7% (SI Appendix, Table S6). De-
spite the use of a DP6 fragment for the crystallization, additional
difference density observed in front of the Fab complementarity
determining regions (CDRs) was compatible with the modeling
of three RUs. The glycan fragment included in the final structure
is herein indicated as a trisaccharide with the three individual
RUs identified as A′, B′, and C′ units. Weak electron density
beyond the A′ RU departing from the binding pocket suggested
that further glycan residues could not be accommodated.
Moreover, this residue appears to be 6-phosphorylated at the C′
unit, suggesting that the Fab bound to either the upstream end or
an internal fragment, and 1-phosphorylated at the A′ ring, a
clear indication that additional residues are extending out of it.
A close inspection of the electron density reveals that the tri-
saccharide is characterized by a variable O-acetylation pattern,
with the two external A′ and C′ units acetylated at C-3 and the
central and most buried B′ unit acetylated at C-4 (Fig. 4 A
and B).
Electron density maps of the Fab fragment were of good
overall quality, allowing the modeling of residues Q1 to C129
and G134 to G215 from the H-chain and residues D1 to N217
from the L-chain of the molecules’ HL and MN copies. In the
case of the OP molecule, no clear electron density was visible on
the constant regions (i.e., residues V112 to G215 of the H-chain
and E110 to N217 of the L-chain).
Pairwise structural superimposition among the different copies
of the complex present in the asymmetric unit resulted in an
overall Cα rmsd value of 0.276 Å (Cα rmsd of 0.305 Å in the
CDRs); therefore, they were considered essentially identical
within the limits of experimental error. The mean pairwise rmsd
in the atomic positions of the three trisaccharide copies bound to
the Fab was 0.33 Å, indicating that the conformation of the
Fig. 3. Epitope mapping of MenA DP6 and de-O-Ac-DP6 OS complexed with a mAb by STD NMR. (A) Native MenA DP6 (green) and de-O-Ac-DP6 (magenta)
STD-NMR spectra were run with a 1:100 mAb/OS mixture. The irradiation frequency was set at 7.00 ppm, and a saturation time of 2 s was used (t = 303 K for
DP6 and 298 K for de-O-Ac-DP6). All STD intensities were normalized against the O-acetyl moiety. (B) Zoomed-in view of the acetyl region of DP6 (green). (C)
Color code indicating the magnitude of the normalized intensities: red, 100 to 85%; orange, 85 to 70%; yellow, 70 to 40%).







































saccharide is also highly similar. Consequently, one copy (MN)
was used for the description of the structure.
The antigen-binding site is a small linear groove in the inter-
face of CDR L1-L3 and CDR H1-H3 (Fig. 4A) with approximate
dimensions of 21.4 Å long, 8.6 Å wide, and 8.4 Å deep. All three
RUs of the trisaccharide are involved in multiple interactions
with the antibody (Fig. 4 C and D). The RU B′ is mostly engulfed
between CDR L1 and L3 and CDR H1 and H3, accounting for
the majority of intermolecular contacts on complex formation.
Within a secondary shallower binding pocket formed by CDR L1
and L3 and CDR H1 and H2 is the RU A′, whereas the RU C′’
makes most of its contacts with CDR L2 and H3 and is the re-
gion of the ligand mostly exposed to the solvent, consistent with
its higher levels of B factors (SI Appendix, Fig. S7). The light-
chain leaflet CDR is dominated by aromatic side chains (Y31,
Y37, H39, Y54, F60, and Y101) (Fig. 4C, Right), while the heavy-
chain CDR is populated by polar side chains—i.e., two Asn
residues (N50, N59) and some positively charged residues (R100
and H35) (Fig. 4C, Left)—in a complementary interplay with the
electropositive patches of the glycan, notably in the methyl
groups of the O-acetyl and N-acetyl substituents, and its overall
hydrophilic character (SI Appendix, Fig. S8). Crucially, the pos-
itive electrostatic potential along the CDR moieties in the
hypervariable domains of the Fab contributes to the electrostatic
attraction of the MenA trisaccharide backbone phosphodiester,
most likely resulting in an increased capacity of the Fab to attract
the negatively charged phosphodiester moieties.
The glycan RU B′ establishes the largest number of interac-
tions, donating a H-bond to the side chain N96 (L) through its
3-OH group, while the carbonyl of the 4-O-acetyl moiety accepts
a H-bond from H39 (L). In addition, the 2-N-acetyl carbonyl
moiety accepts a H-bond from the phenol side chain of Y101 (L).
Importantly, the electron-withdrawing character of the B′ 2-N-
acetyl group leads to a polarization effect on the methyl groups,
which become more acidic. These polarized methyl groups are
within 4 Å of residues Y31 (L) and Y37 (L) and act as good CH-
π donors (40, 41). Conversely, these aromatic side chains are in
turn involved in an extended network of H-bonds. Remarkably,
Y31 (L) donates a H-bond to the A′ 1-phosphate group, whereas
Y37 (L) donates a H-bond to the phosphodiester appended
between the subunits B′ and C′, which is engaged in a bidentate
H-bond with electropositive K55 (L), resulting in increased
Fig. 4. X-ray crystallographic structure of the Fab in complex with a MenA trisaccharide. (A) Surface representation of the variable light (VL) and heavy chain
(VH) of the Fab, colored in cyan and orange, respectively. MenA trisaccharide, represented as gray sticks, is located at the interface between the heavy chain
and light chain CDRs. (B) 2mFo-DFc electron density map (blue mesh, contoured at 1.0 σ) of the modeled MenA trisaccharide fragment bound to the Fab. The
trimer exhibits a 3-O-acetylation in units A’ and C’ and 4-O-acetylation in unit B’. (C) Zoomed-in view (Left) and 180° rotation (Right) of the interactions of
MenA trisaccharide with the different CDR residues depicted in sticks, with a color-coding scheme reflecting the CDR classification (CDR L1, green; CDR L2,
teal; CDR L3, blue; CDR H1, pink; CDR H2, magenta; CDR L3, yellow) according to North et al. (39) (SI Appendix, Fig. S8).
Fig. 5. Docked-minimized structures of complexes between bactericidal mAb and MenA DP3 OS with different O-acetylation patterns. The amino acids
differing in their interaction with 4-OAc, 3-Oac, and de-OAc units of the three residues A’ (A), B’ (B), and C’ (C) of MenA trisaccharide are indicated.



























































electronegativity of the former π-system, making them good CH-
π acceptors (42).
Concerning the glycan RU A′, the 3-O-acetyl ether group
receives a H-bond from the N59 (H) amide side chain, whereas
the OH-4 acts as a H-bond acceptor from the N50 (H) amide
side chain. Of note, the closely positioned H35 (H) donates a
H-bond to the phosphodiester appended between the subunits A
′ and B′, which in turn makes a second H-bond with a coordi-
nated water molecule bridging two additional H-bonds to the
W33 (H) and V99 (H) backbone carbonyl and amine groups,
respectively. Although no major interactions are established by
the A′ 2-N-acetyl group and the binding pocket, the former
amide is positioned well to establish an intramolecular H-bond
with the B′ 2-N-acetyl group carbonyl group.
Finally, concerning the glycan RU C′, the 3-O-acetyl carbonyl
moiety is within H-bond distance from the guanidino group of
R100 (H) residue. As previously described for unit B′, the po-
larized methyl group of 2-N-acetyl moiety is involved in a CH–π
interaction with the Y54 (L) residue, with the latter further en-
gaged in a H-bond with the terminal C′ 6-phosphate group.
In Silico Docking Experiments of Different O-Acetylation Patterns.
Interestingly, the O-acetyl groups are involved in several inter-
actions within the binding pocket, and their presence affects the
H-bond network established with the Fab fragment. Although
the crystallized complex shows a 3-4-3 O-acetylation pattern in
the trisaccharide epitope, the natural PSs present multiple
combinatorial possibilities of O-acetylation. Thus, we asked
whether alternative patterns of O-acetylation would still result in
stable interactions with the bactericidal mAb.
Docking-minimization protocols performed for the complexes
formed between the Fab and diverse 3-mer with different acet-
ylation patterns identified de-O-acetyl, 3-O-acetyl, and 4-O-ace-
tyl OSs as potential ligands (Fig. 5A and SI Appendix, Figs. S9
and S10). According to the calculations, the complexes were
conformationally stable, and most of the stabilizing contacts
were maintained. However, acetylation in certain positions
allowed the establishment of additional interactions with the
antibody, which in turn could provide an increased binding af-
finity. In particular, the contacts between unit B′ and H39 (L) are
maintained after minimization irrespective of the acetylation
pattern (Fig. 5B). Modeled complexes with either Ne2-H or Nδ1-
H tautomeric states for H39 (L) showed key contacts between
OH in positions 3 and 4 and the imidazole ring of that residue,
which was easily relocated depending on the acetylation pattern.
In contrast, the 3-O-acetyl group of C′ was key to maintaining
the contacts with R100 (H), and their absence or shift to position
4 would abolish this interaction (Fig. 5C). Similarly, deacetyla-
tion of unit A′ would statistically diminish the number of hy-
drogen bond acceptor atoms able to interact with N59 (H) and
N50 (H) (Fig. 5C and SI Appendix, Fig. S9).
Preferential Recognition of O-Acetylated Glycotope by Human
Polyclonal Serum. To explore whether the mapped acetylated
trisaccharide epitope is representative of the immune response
elicited in humans by MenA conjugate, a competitive serum
bactericidal activity (SBA) assay was conducted (43). To this end,
human sera, elicited by immunization with the MenACWY-CRM197
Fig. 7. Model of interaction of the trimer epitope mapped out of the
hexamer structure and impact of O-acetylation pattern. 3-O-acetylation at C’
residue (red labeled) seems crucial for binding (A), and thus could trigger a
more rigid initial interaction of this residue. Variable O-acetylation patterns
(yellow) appear acceptable in the A′ and B′ RUs, suggesting that those res-
idues could rotate (B) until they find proper engagement with the binding
pocket (C).
Fig. 6. Inhibition of human SBA using MenA fragments of different
lengths. Inhibitors at different concentrations were preincubated with
pooled human immune serum, followed by exposure to a bacterial strain in
the presence of human complement. Bars represent mean values, and the
error bars represent the SD of the mean from triplicate experiments.







































vaccine, was preincubated with diverse inhibitors at different con-
centrations, followed by evaluation of their human complement-
mediated bactericidal activity.
Fragments with a length of DP3 to DP5 were able to inhibit
complement- mediated killing of meningococcus at a concen-
tration of 1 mM (Fig. 6). In contrast, DP6 substantially inhibited
the sera from binding to the pathogen capsule at a lower con-
centration of 0.2 mM, similar to DP20 and PS. Conversely, de-O-
acetyl DP6 did not provide SBA inhibition (Fig. 6). These data
indicate that DP3 is the minimal length antigenic epitope rec-
ognized by immune human sera, and that lengths longer than
DP5 show higher serum depletion because of increased avidity.
Discussion
Glycoconjugate vaccines are a well-established means of eliciting
protective antibodies toward PS surrounding the surface of
pathogens (44). Despite this success, however, elucidation of the
molecular basis of recognition of antigenic glycan epitopes by
bactericidal antibodies at atomic resolution remains a challenge
in structural glycobiology (45). Owing to the refractory nature of
glycans to crystallize, information on the structural requirements
of antigen recognition has been mainly gathered via combina-
tions of various techniques, including SPR, isothermal titration
calorimetry, NMR spectroscopy (46–52), and, more recently,
single particle cryo-electron microscopy (53, 54).
Here we showcase an integrated approach to map, at atomic
detail, the minimal antigenic epitope of the MenA capsular PS,
uncovering with unprecedented detail the length and O-acetyl
pattern engaged in molecular recognition with a bactericidal
mAb. O-acetylation has been hypothesized to be an important
attribute for meningococcal vaccine efficacy (30). Inhibition
ELISA with anti-MenA polyclonal serum and a bactericidal mAb
showed a length-dependent recognition. Importantly, a trimer
portion of the PS was sufficient to establish strong binding. In
agreement with these data, SPR showed dissociation kinetics
decreasing progressively from DP2 to DP5, with the off-rate ki-
netics reaching a plateau for fragments longer than 3 RUs. On
the other hand, de-O-acetylated DP5 resulted in abrogation of its
binding. STD-NMR experiments unraveled a preferential
transfer of saturation toward both O- and N-acetyl groups,
thereby confirming their engagement on complex formation.
Consistent with these findings, the crystal structure of the
Fab:DP6 complex solved at 2.67 Å resolution revealed a trimer
antigenic determinant adopting a linear bound conformation,
with an alternating 3-4-3 O-acetylation pattern. The antigen
recognition is governed by several types of interactions with
different natures, mainly H-bonds, hydrophobic and electrostatic
interactions, and van der Waals forces. Fittingly, the binding
pose reveals that all O-acetyl moieties are engaged in H-bond
networks, and docking studies with deacetylated MenA homo-
logs highlight their relevance in the interaction, while all but one
N-acetyl are interacting with the bactericidal mAb.
Remarkably, while the 3-O-acetyl of the C′ glycan residue
seems to confer a greater specificity in engagement of the
binding pocket, A′ and B′ moieties show greater promiscuity
toward other O-acetylation patterns, thus conferring a higher
plasticity to the mAb (Fig. 7). Furthermore, the resolved trimer
was part of a longer structure, of which the mAb bound to either
an internal position or an upstream portion. The Ab recognition
does not seem to affect the canonical conformation of the sugar
in solution.
Finally, the human complement-mediated bactericidal activity
of sera from previously vaccinated subjects was efficiently
inhibited by fragments with lengths of 3 to 5 RUs, although
higher inhibitory concentrations were needed compared with
DP6 and fragments longer than DP20 because of their lower
avidity. In contrast, a de-O-acetylated DP6 was not able to inhibit
the serum bactericidal activity, confirming that vaccine-induced
immune responses in humans are also directed to theO-acetylated
trimer epitope.
Our findings clearly demonstrate that the O-acetylated trimer
MenA epitope is involved in the molecular recognition of anti-
bodies elicited by immunization with MenA PS-based vaccines
and likely by preexposition to the heavily encapsulated menin-
gococcus. While the epitope is a short trimer, our data also show
that its multimeric exposition in the polysaccharide capsule favors
avidity interactions that further strengthen antibody binding and aid
complement deposition. The unique features of the antigenic de-
terminant of MenA capsular PS elucidated by this study add to our
understanding of the molecular basis of the immune recognition of
carbohydrate haptens and pave the way for the rational design of
improved vaccines (17) and therapeutics (9).
Materials and Methods
Recombinant murine Fab was purified in 20 mM PBS and 150 mMNaCl pH 7.1
and then concentrated to 15 mg/mL using a centrifugal device with a 10-kDa
cutoff membrane (Amicon Ultra; Millipore Sigma). The complex between DP6
and the Fab was prepared by incubation at 4 °C (10:1 molar ratio of sac-
charide:Fab) and then subjected to crystallization trials using a Crystal
Gryphon liquid handling robot (Art Robbins Instruments). Details of the
crystallization of the complex are reported in SI Appendix.
Competitive SBA was performed with pooled human antibodies obtained
via a Phase II clinical trial V102_02 (ClinicalTrials.gov identifier NCT01210885)
conducted at multiple sites (Panama and Chile) with Menveo vaccine under
the approval of the local Ethical Committee. The samples, which were
obtained on written informed consent from study participants, were dei-
dentified before use in the reported analysis. The experimental protocol is
described in SI Appendix.
Experimental methods for OS generation, inhibition ELISA, SPR mea-
surements, STD NMR experiments, cocrystallization of the Fab-glycan com-
plex, and in silico modeling are provided in SI Appendix.
Data Availability.All study data are included in themain text and SI Appendix.
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